Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239222 · ClinicalTrials.gov registry record · NA
Feasibility Study to Evaluate a New Energy Storage and Return Prosthetic Foot
A NA study, sponsored by Otto Bock Healthcare Products.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT04239222 is a NA study that has completed, run by Otto Bock Healthcare Products. The registered enrollment target is 27 participants.
The verdict
NCT04239222, a NA study, has completed, sponsored by Otto Bock Healthcare Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
A prospective, interventional, multicenter pilot study to characterize differences in performance and patient reported outcomes between the Taleo, Proflex XC, and the new Revo prosthetic foot.
Interventions
- DEVICE Revo-M
- DEVICE Taleo
- DEVICE Proflex XC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2022-03-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04239222
The ClinicalTrials.gov registry entry for NCT04239222 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otto Bock Healthcare Products, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Revo-M is the first listed.
NCT04239222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04239222 about?
NCT04239222 is a clinical study titled "Feasibility Study to Evaluate a New Energy Storage and Return Prosthetic Foot". A prospective, interventional, multicenter pilot study to characterize differences in performance and patient reported outcomes between the Taleo, Proflex XC, and the new Revo prosthetic foot.
What is the current status of trial NCT04239222?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2020-03-10. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT04239222?
The interventions under investigation include: Revo-M (DEVICE), Taleo (DEVICE), Proflex XC (DEVICE).
Who is sponsoring clinical trial NCT04239222?
This trial is sponsored by Otto Bock Healthcare Products, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.